231 filings
Page 4 of 12
8-K
6c5465sjn5
2 Sep 21
Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance
4:05pm
EFFECT
5n95rr
8 Jun 21
Notice of effectiveness
12:15am
8-K
ykx0x34s7w rbfp
4 Jun 21
Departure of Directors or Certain Officers
4:05pm
CORRESP
2c5lzeg22
3 Jun 21
Correspondence with SEC
12:00am
UPLOAD
jwqxxfz
3 Jun 21
Letter from SEC
12:00am
8-K
cxrixg cznqi8m
10 May 21
Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update
4:06pm
S-8
t2nm1i2t znkg
8 Apr 21
Registration of securities for employees
4:06pm
8-K
2l094ivg
24 Mar 21
Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update
8:01am
8-K
m2bz ue64y0cl1ds
10 Nov 20
Regulation FD Disclosure
4:07pm
8-K
z0xyady6h3r18n
9 Nov 20
Forte Biosciences, Inc. Announces Third Quarter 2020 Results and Provides General Business Update
4:56pm
8-K
j0ww3bhv5vn n995lc6
29 Oct 20
Other Events
5:28pm
424B5
p5mx luabo8
29 Oct 20
Prospectus supplement for primary offering
5:25pm
424B5
m79brwsrswqmz2j
28 Oct 20
Prospectus supplement for primary offering
5:29pm